Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RIG-I-like receptors (RLRs) are a family of intracellular pattern recognition receptors functioning as key sensors for viral RNA within the cytoplasm, essential for the innate immune response to viral infection. The best characterized member, RIG-I (DDX58), detects 5'-triphosphorylated double- or single-stranded RNA from viruses and initiates a signaling cascade via the adaptor MAVS, ultimately inducing transcription of type I interferons and pro-inflammatory cytokines[2][1][3][4][5]. Other members include MDA5, which preferentially binds long dsRNA, and LGP2, which modulates the activity of RIG-I and MDA5. RLR signaling protects against diverse RNA viruses but must be tightly regulated; dysregulation or chronic activation can contribute to autoimmune and autoinflammatory conditions as well as pathology in infection and cancer settings[4][5][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RIG-I-like receptor (RLR).